Factory Mutual Insurance Co. cut its position in shares of Allergan PLC. (NYSE:AGN) by 1.4% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 500,700 shares of the company’s stock after selling 7,000 shares during the period. Allergan PLC. accounts for 1.4% of Factory Mutual Insurance Co.’s investment portfolio, making the stock its 11th largest position. Factory Mutual Insurance Co. owned approximately 0.15% of Allergan PLC. worth $121,715,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also modified their holdings of the company. Crestwood Advisors Group LLC purchased a new position in Allergan PLC. during the first quarter valued at about $103,000. Feltz Wealth PLAN Inc. purchased a new position in Allergan PLC. during the first quarter valued at about $107,000. Enterprise Financial Services Corp raised its position in Allergan PLC. by 62.7% in the first quarter. Enterprise Financial Services Corp now owns 462 shares of the company’s stock valued at $110,000 after buying an additional 178 shares during the last quarter. Jacobi Capital Management LLC raised its position in Allergan PLC. by 4.9% in the first quarter. Jacobi Capital Management LLC now owns 472 shares of the company’s stock valued at $112,000 after buying an additional 22 shares during the last quarter. Finally, JNBA Financial Advisors raised its position in Allergan PLC. by 2.5% in the first quarter. JNBA Financial Advisors now owns 487 shares of the company’s stock valued at $116,000 after buying an additional 12 shares during the last quarter. Institutional investors and hedge funds own 83.63% of the company’s stock.
Allergan PLC. (NYSE AGN) traded down 0.213% during midday trading on Tuesday, hitting $232.145. The stock had a trading volume of 594,743 shares. The firm has a market cap of $77.61 billion, a price-to-earnings ratio of 7.073 and a beta of 1.16. Allergan PLC. has a 52 week low of $184.50 and a 52 week high of $256.80. The firm has a 50 day moving average of $245.54 and a 200 day moving average of $238.65.
Allergan PLC. (NYSE:AGN) last issued its earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.95 by $0.07. The company had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The firm’s quarterly revenue was up 8.8% on a year-over-year basis. During the same quarter last year, the company earned $3.35 EPS. Equities research analysts predict that Allergan PLC. will post $16.27 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 15th. Investors of record on Friday, August 18th will be paid a dividend of $0.70 per share. This represents a $2.80 annualized dividend and a yield of 1.20%. The ex-dividend date is Wednesday, August 16th. Allergan PLC.’s dividend payout ratio (DPR) is presently 9.95%.
ILLEGAL ACTIVITY NOTICE: “Factory Mutual Insurance Co. Reduces Position in Allergan PLC. (AGN)” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://sportsperspectives.com/2017/08/15/factory-mutual-insurance-co-reduces-position-in-allergan-plc-agn.html.
AGN has been the subject of several recent analyst reports. Zacks Investment Research raised shares of Allergan PLC. from a “hold” rating to a “buy” rating and set a $270.00 price objective for the company in a research report on Tuesday, July 11th. Goldman Sachs Group, Inc. (The) downgraded shares of Allergan PLC. from a “buy” rating to a “neutral” rating and set a $262.00 price objective for the company. in a research report on Wednesday, May 10th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Allergan PLC. in a research report on Thursday, May 25th. Royal Bank Of Canada raised their price objective on shares of Allergan PLC. from $279.00 to $284.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 10th. Finally, Deutsche Bank AG reaffirmed a “buy” rating and set a $273.00 price objective (up previously from $265.00) on shares of Allergan PLC. in a research report on Monday, July 17th. Eight investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Allergan PLC. currently has an average rating of “Buy” and an average target price of $275.49.
In related news, Director Nesli Basgoz sold 1,889 shares of Allergan PLC. stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $220.45, for a total transaction of $416,430.05. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.36% of the stock is currently owned by company insiders.
About Allergan PLC.
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.